EncrypGen Announces Strategic Partnership With BTblock, Expands Board Of Directors.

EncrypGen, Inc., the world’s first blockchain-mediated genomic data company, has entered into a strategic partnership with BTblock, LLC, an emerging technology and cybersecurity consultancy firm founded by seasoned entrepreneurs with an established record of building value through the creation, growth and sale of successful businesses. As part of the partnership, BTblock co-founder & Chief Strategy Officer David M. Garrity, CFA has joined the board of EncrypGen.

An experienced technology and finance professional, Mr. Garrity has advised clients such as The World Bank Group on technology issues and currently serves as Independent Director on the Board of BTCS Inc., a publicly-held U.S. company involved with Digital Assets and Blockchain. Mr. Garrity has served previously as CFO and Board Director at two publicly-traded technology companies. Separately, Mr. Garrity regularly contributes on CNBC, Bloomberg, and Business News Network.

“The BTblock team has significant experience in real-world blockchain applications and commercialization as well as fundamental experience in business development that will be instrumental to EncrypGen. This partnership will help us to further leverage our historic breakthrough in the development and launch of the Gene-Chain, a proprietary blockchain used to mediate the searching, storing, sharing, buying and selling of genomic data. With their strong history of business growth, commercialization, and marketing expertise, BTblock brings EncrypGen closer to the broad adoption of our technology, and nearer to a world where everyone owns their own DNA data and can realize direct economic benefit from its use in medical research.” said Dr. David Koepsell, EncrypGen co-founder and CEO.

On the goals for the partnership, Mr. Garrity said, “BTblock is focused on bringing to market solutions that both strengthen current systems and deliver new avenues for secure data storage and sharing. With demand growing globally for faster and more tailored pharmaceutical solutions, the research need for DNA data is expanding. Current business models, however, actually restrict scientific discovery because the majority of genomic labs either can’t afford or cannot access DNA data which is being sold on an exclusive basis. In marked contrast, EncrypGen offers greater data availability while facilitating self-sovereign identity through individuals continuing to own their DNA data.”

EncrypGen, Inc.
8 The Green STE B
Dover, DE 19901 | (509) 768-2249
Dr. David Koepsell (954)955-9015 drkoepsell@encrypgen.com

About EncrypGen:
EncrypGen, Inc. creates software that empowers consumers, researchers, and businesses to share genetic data. Founded in 2016, the EncrypGen mission is to leverage blockchain technology to provide greater privacy for the sharing of genomic data for individuals, and to give them a means to sell their data via a digital asset, the DNA token, and simultaneously make more data available for scientists. For more information, please visit www.encrypgen.com.

About BTblock:
BTblock, LLC is an emerging technology and cybersecurity consultancy firm founded by seasoned entrepreneurs with an established record of building value through the creation, growth and sale of successful businesses. BTblock enables ideation, validation, and implementation in bringing innovations to market. For more information, please visit www.btblock.io.

This release was published on openPR.